SAB Biotherapeutics
SABS
37 hedge funds and large institutions have $93.6M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
371% more capital inflows, than outflows
Capital inflows: $34M | Capital outflows: $7.23M
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
42% more funds holding
Funds holding: 26 → 37 (+11)
18.23% more ownership
Funds ownership: 45.33% → 63.55% (+18%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Glazer Capital LLC
New York
|
+$5.28M |
| 2 |
Kepos Capital
New York
|
+$5.24M |
| 3 |
Karpus Investment Management
Pittsford,
New York
|
+$4.38M |
| 4 |
Boothbay Fund Management
New York
|
+$3.97M |
| 5 |
CVI Holdings
Wilmington,
Delaware
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mangrove Partners
Greenwich,
Connecticut
|
-$5.09M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$979K |
| 3 |
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$496K |
| 4 |
Mizuho Securities USA
New York
|
-$205K |
| 5 |
Wolverine Asset Management
Chicago,
Illinois
|
-$182K |
SABS Hedge Fund Activity: Q2 2021 in Review
37 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2021, worth a combined $93.6M — up 42% from $65.9M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SABS positions and 4 closed out — a net gain of 11 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $5.28M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.09M sold.
- 37 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2021, up from 26 in Q1 2021.
- Funds reported $93.6M of SAB Biotherapeutics stock for Q2 2021, up 42% quarter-over-quarter.
- 15 funds opened new SAB Biotherapeutics positions in Q2 2021 and 4 closed out, a net change of +11 holders.
- The largest SAB Biotherapeutics buyer in Q2 2021 was Glazer Capital LLC, an estimated $5.28M added.
- The largest SAB Biotherapeutics seller in Q2 2021 was Mangrove Partners, an estimated $5.09M sold.
Based on aggregated 13F filings for Q2 2021.